Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly reacquired AK-01—originally discovered internally then sold to TVM Capital's AurKa vehicle in 2016—signaling that the asset's Phase 1 oncology data…
AK-01 described as 'first-in-class' Aurora kinase A inhibitor with 'high selectivity for Aurora A'; Lilly's milestone-heavy structure ($465M of $575M tied to…
Acquisition gave Lilly full rights to AK-01 in solid tumors after Phase 1 dose-escalation; positioned as a strategic refill of an oncology asset divested in…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Eli Lilly acquired AurKa Pharma, gaining the Aurora A kinase inhibitor AK-01 (LY3295668) for solid tumors. Total deal value up to $575M with $110M upfront and $465M in development and regulatory milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / AurKa Pharma Inc. (this deal) | 2019 | $575M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2019 deals · Eli Lilly and Company deals · Oncology deals